Trastuzumab is considered the key drug for treatment of HER2-positive breast cancer patients. It improves patient survival; however, resistance to trastuzumab remains a challenge in HER2-positive breast cancer patients. Therefore, the prediction of response to trastuzumab is crucial to choose optimal ...
2.Schettini F,Chic N,Brasó-Maristany F,et al.Clinical,pathological,and PAM50 gene expression features of HER2-low breast cancer [published correction appears in NPJ Breast Cancer.2023 Apr 29;9(1):32.doi:10.1038/s41523-023-00538-x].NPJ Breast Cancer.2021;7(1):1.Published 2021 Jan 4.d...
Discovery Of Gene That Causes HER2 Breast Cancer To Spread Raises Hope For New TreatmentScientists in Scotland have identified a gene that plays a key role in the spread of HER2 positive to other parts of the body, raising hopes of a new treatment for this common form of breast cancer....
Approximately 15%–30% of breast cancers have overexpression or amplification of human epidermal growth factor receptor 2 (HER2), which is associated
Approximately 15–20% of human epidermal growth factor receptor 2 (HER2) is amplified and/or overexpressed in breast cancer [5]. HER2-positive BRCA is highly invasive, with short disease-free survival and poor prognosis. The HER2 gene (also known as HER2/neu, c-erbB-2) is located at 17...
of times this article has been viewed Abstract: Amplification of the HER2 gene and/or overexpression of its protein product have been found in up to 25% to 30% of human breast cancers and have been shown to be associ- ated with poorer outcomes compared to 'HER2 normal' breast cancer. Re...
Currently, the human epidermal growth factor receptor 2 (HER2) status of breast cancer is classified dichotomously as negative or positive to select patients for HER2-targeted therapy. However, with the introduction of novel treatment options, it is important to get more insight in the biology of...
Alpelisib(Piqray) is a P13K inhibitor in pill form that can be used with fulvestrant in women with advanced HR+, HER2-negative breast cancer with a PIK3CA gene mutation. Sacituzumab govitecan(Trodelvy) is a monoclonal antibody with an attached chemotherapy drug. It is used to treat some adva...
BEIJING, July 15 (Xinhua) -- Chinese researchers have developed nanoparticles to treat a more aggressive type of breast cancer. Human epidermal growth factor 2 (HER2) is a type of protein in the breast tissue, helping control breast cells to divide, grow and repair. When the HER2 gene is ...
HER2 is an established therapeutic target in a large subset of women with breast cancer; a variety of agents including trastuzumab, pertuzumab, lapatinib, neratinib and trastuzumab emtansine (T-DM1) have been approved for the treatment of HER2-positive breast cancer. HER2 is also overexpressed in ...